Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFutura Medical Regulatory News (FUM)

Share Price Information for Futura Medical (FUM)

Share Price is delayed by 15 minutes
Get Live Data
0.546    -0.034 (-5.86%)
Bid:
0.55
Ask:
0.60
Spread: 0.05 (9.091%)
Market Cap: £3.17m
FUM Live PriceLast checked at - London Stock Exchange

Intraday Futura Medical Share Chart

AGM Statement

24 Jun 2019 16:42

RNS Number : 2473D
Futura Medical PLC
24 June 2019
 

Results of Annual General Meeting

24 June 2019

Futura Medical plc (AIM: FUM) ("Futura" or the "Company"), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal Dermasys® drug delivery technology currently focused on sexual health and pain, announces that at its Annual General Meeting, held earlier today, all resolutions were duly passed by the shareholders.

 

For further information please contact:

Futura Medical plc James Barder, Chief ExecutiveAngela Hildreth, Finance Director and COO

Email: Investor.relations@futuramedical.comTel: +44 (0) 1483 685 670

Nominated Adviser and Sole Broker:LiberumBidhi Bhoma/ Euan Brown/ Kane CollingsTel: +44 (0) 203 100 2000

 

For media enquiries please contact:

Optimum Strategic Communications

Mary Clark/ Eva Haas/ Hollie Vile

Email: futuramedical@optimumcomms.com

Tel: +44 (0) 203 950 9144

 

Notes to editors:

 

About Futura Medical plc

Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal Dermasys® drug delivery technology. These products are optimised for clinical efficacy, safety, administration and patient convenience and are developed for the prescription and consumer healthcare markets as appropriate. Current therapeutic areas are sexual health, including erectile dysfunction, and pain relief. Development and commercialisation strategies are designed to maximise product differentiation and value creation whilst minimising risk.

 

The first European Phase 3 study for MED2005, referred to as "FM57", is a 1,000 patient, dose-ranging, multi-centre, randomised, double blind, placebo-controlled, home use, parallel group study of MED2005 0.2%, 0.4% and 0.6% Glyceryl Trinitrate for the treatment of erectile dysfunction with an open label extension. FM57 is progressing on track, with headline data expected by the end of 2019.

 

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange. www.futuramedical.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
RAGCKQDNPBKDFAB
Date   Source Headline
30th Jan 201411:55 amRNSTR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
27th Jan 20147:00 amRNSUS Roll-out of PET500
13th Jan 20144:45 pmRNSRemuneration of Non-Executive Directors
6th Jan 20147:00 amRNSNotification of Major Interest in Shares
19th Dec 20137:00 amRNSLicenses CSD500 to RFSU AB in the Nordic Region
6th Dec 20137:00 amRNSLicenses CSD500 to Ansell in China
5th Dec 201311:47 amRNSNotification of Major Interest in Shares
19th Nov 20133:27 pmRNSNotification of Major Interest in Shares
18th Nov 20139:57 amRNSNotification of Major Interest in Shares
31st Oct 201312:45 pmRNSTotal Voting Rights
17th Oct 20137:00 amRNSAward of CE Mark Certificate
3rd Oct 20137:00 amRNSEquity Research Service
2nd Oct 201310:55 amRNSBlock Listing Update
1st Oct 20137:00 amRNSTotal Voting Rights
24th Sep 201310:18 amRNSDirector Share Dealings
24th Sep 20139:25 amRNSGrant of Options
23rd Sep 20135:43 pmRNSDirector Share Dealings
16th Sep 20137:00 amRNSAppointment of Nomad & Broker
12th Sep 20137:00 amRNSInterim Results
9th Sep 20137:00 amRNSPositive Opinion for CSD500
20th Aug 20132:21 pmRNSNotification of Major Interest in Shares
1st Jul 20137:00 amRNSPain Relief Portfolio
6th Jun 201312:04 pmRNSNotification of Major Interest in Shares
31st May 20133:06 pmRNSTotal Voting Rights
22nd May 20137:00 amRNSBlock Listing Update
21st May 20137:00 amRNSNotification of Interim Results
9th May 20137:00 amRNSDirector Share Dealings
7th May 20135:06 pmRNSResult of AGM
7th May 20137:00 amRNSAGM Statement
30th Apr 20134:17 pmRNSTotal Voting Rights
16th Apr 20137:00 amRNSDirector Share Dealings
9th Apr 20137:00 amRNSDirector Share Dealing
4th Apr 20132:25 pmRNSDirectors' Share Dealings
2nd Apr 20137:00 amRNSLicenses CSD500 to Church & Dwight
26th Mar 20137:00 amRNSNotice of AGM
13th Mar 20133:52 pmRNSNotification of Major Interest in Shares
7th Mar 20137:00 amRNSPreliminary Results
31st Jan 20137:00 amRNSTotal Voting Rights
14th Jan 20137:00 amRNSNotification of Preliminary Results
11th Jan 20135:20 pmRNSNotification of Major Interest in Shares
7th Jan 20134:10 pmRNSStatement re Share Price Movement
2nd Jan 20134:23 pmRNSRemuneration of NEDs
22nd Nov 20127:00 amRNSBlock Listing Update
31st Oct 201211:33 amRNSTotal Voting Rights
12th Oct 20123:05 pmRNSNotification of Major Interest in Shares
5th Oct 20122:59 pmRNSDirector's Dealings
28th Sep 20127:00 amRNSTotal Voting Rights
21st Sep 20123:23 pmRNSNotification of Major Interest in Shares
20th Sep 201212:27 pmRNSNotification of Major Interest in Shares
17th Sep 20129:00 amRNSGrant of Options

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.